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Full-thickness skin biopsies obtained from four patients with 
rapidly progressive diffuse fasciitis associated with the Eosin-
ophilia-Myalgia syndrome (EMS) were examined for the ex-
pression of transforming growth factor-/31(TGF-/31), type VI 
collagen, and fibronectin genes employing immunohisto-
chemistry and in situ hybridizations. The immunohistoche-
mical studies demonstrated increased deposition of TGF-fJ, 
type VI collagen, and fibronectin epitopes in the extracellular 
matrix of the fascia in comparison to the adjacent dermis in 
the same specimens. Increased levels of type VI collagen 
mRNA, as evidenced by positive in situ hybridization signals 
T he Eosinophilia-Myalgia syndrome (EMS) is a re-cently recognized clinical entity characterized by the development of severe myalgias and peripheral blood eosinophilia in association with the consumption of L-tryptophan-containing products ( 1 - 8). The disease 
reached epidemic proportions in the United States in late 1989, and 
to date more than 1500 cases have been reported to the Centers for 
Disease Control. The emerging clinical picture of patients affected 
with EMS indicates that in a substantial proportion of cases the 
disease evolves into a chronic, multi-systemic illness despite the 
discontinuation of L-tryptophan (8] . Among the clinical features 
that develop during the chronic phase of the illness, diffuse sclero-
derma-like cutaneous changes are prominent. Clinically, the af-
fected skin appears hyperpigmented, markedly indurated, and 
tightly bound to the underlying tissues. Involvement is most c?~­
mon in the lower extremities and may affect the upper extremltles 
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Abbreviations: 
eDNA: complementary deoxyribonucleic acid 
EMS: eosinophilia-myalgia syndrome 
mRNA: messenger ribonucleic acid 
PAP: peroxidase anti-peroxidase 
SSC: standard saline citrate 
TBS: Tris-buffered saline 
TGF-P, : transforming growth factor-p, 
with an a2(VI) collagen eDNA, were also found in the fascia 
in comparison with the dermis. In situ hybridizations of af-
fected fascia with a human sequence-specific TGF-/31 eDNA 
demonstrated numerous fibroblasts displaying positive hy-
bridization signals indicative of high levels of transcripts for 
this cytokine. In contrast, no hybridization signal for TGF-/31 
was detected in fibroblasts in the adjacent dermis. These find-
ings suggest that TGF-/31 may play an important role in the 
development of the connective tissue alterations present in 
EMS-associated diffuse fasciitis. J Invest Dermatol 96:20-25, 
1991 
and the trunk, whereas the hands, feet, and face are usually spared. 
The pathologic hallmarks of the chronic cutaneous involvement in 
this syndrome are inflammation and fibrosis of the fascia occasion-
ally extending to the lower dermis and subjacent muscle. Tissue 
infiltration with eosinophils is freguently present, particularly in 
the early stages of the disease ( 4-8 J. 
Although the precise etiologic agent and the mechanisms respon-
sible for the clinical and pathologic manifestations of EMS are not 
known at the present time, it is apparent that excessive accumula-
tion of connective tissue in the affected fascia is responsible for the 
remarkable cutaneous alterations observed in these patients. In a 
previous study, we demonstrated that fibroblasts in the affected 
fascia of patients with EMS display elevated expression of type I 
procollagen genes as detected by in situ hybridization with a human 
a1(I) procollagen eDNA [4] . In the present study, we have investi-
gated whether the alterations in the expression of extracellular ma-
trix genes are confined to type I procollagen or whether genes for 
other connective tissue components, such as type VI collagen and 
fibronectin, also show increased expression. In addition, we have 
explored the hypothesis that transforming growth factor-fi1 (TGF-
fi1), a pleiotropic cytokine released from activated lymphocytes, 
which has been shown to stimulate various fibroblast activities [9 -
13], plays a role in the development of the fascial fibrosis in EMS. 
For this purpose, we performed tissue immunolocalization employ-
ing human-specific anti-TGF-fi antibodies and in situ hybridiza-
tions with human sequence-specific TGF-fi1 eDNA. 
METHODS 
Patients Four patients with L-tryptophan -associated EMS who 
developed severe and progressive scleroderma-like cutaneous in-
volvement were studied at the Thomas Jefferson University Hospi-
tal (Table I). The details of their clinical features and laboratory 
abnormalities have been described previously [4] and are briefly 
summarized in Table I. Each case fulfilled the preliminary criteria 
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Table I_ Selected Clinical C haracteristics of Four Patients with Diffuse Fasciitis Associated with EMS 
Age (years)/sex 
Onset of symptoms 
Areas of cutaneous involvement• 
Highest eosinophil count 
, A, arms/forearms; T, trun k/abdo men; L, legs/thi ghs. 
Case 1 
59/F 
8/1989 
A,T,L 
2.4 X 109/l 
for the definition of EMS suggested recently [3] . The clinical appear-
ance of the affected skin was consistent with the diagnosis of diffuse 
fasc iitis in each case . 
Skin Histopathology Full-thickness excisional biopsies that in-
cluded the deep fascia were obtained from affected skin of each 
patient. Sections of paraffin-embedded tissue were stained with he-
macoxylin-eosm, Alctan blue at pH 2. 5, Masson's trichrome, and 
Giemsa stains. 
In situ Hybridization T o investigate the expression ofTGF-,81 
and type VI coll agen genes , in situ hybridizations were performed 
w ith human sequence-specific eDNA, as previously described 
[13,14]. Briefl y, 5-,um-thic_k cryo~ectio ns were cut from snap-fro-
zen biopsy samples, fixed 1mmed1ately w1th paraformaldehyde in 
phosphate-buffered saline for 20 min, and prehybridized under 
conditions described previously [1 3,14] . The tissue specimens were 
hybridized for 16 h at 42o C in a solution containing the 32P-labeled 
eDNA probe. After each hybridization, the specimens were washed 
at a fin al stringency of0.2 X SSC. The (32P]cDNA-mRNA hybrids 
were detected by immersing the samples in autoradiographic emul-
sion (NTB-3, Eastman Kodak, Rochester, NY) and exposing them 
at 4 °C in a des iccant-containing box for 3 -5 d. The samples were 
developed with Kodak D-19 developer, stained with hematoxylin, 
dehydrated with ethanol, cleared with xyl ene, and mounted. For 
detection of type VI coll agen mRNA transcripts, a 1.4-kb human 
a2(VI) collagen eDNA was used [15]. A TGF-,81 eDNA was devel-
oped by polymerase chain reaction amplification. For this purpose, 
mRNA from cultured human fetal skin fibrobl asts was used as tem-
plate for synthesis of eDNA, and a 450-bp region defined by syn-
thetic oligonucleotide primers corresponding to the published 
TGF-,81 sequences [1 6] was amplified by polymerase chain reaction 
[17] . The 0.45-kb eDNA was isolated by agarose gel electrophoresis 
and subcloned into Bluescript KS-vector, and its identity was con-
firm ed by nucleotide sequencing [1 8]. 
Immunolocalization of Type VI Collagen, Fibronectin, and 
TGF-P Epitopes For indirect immunofluorescence, 5-,um-thick 
frozen sections were rinsed with Tris-buffered saline (TBS, pH 7 .6) 
and preincubated for 15 min in TBS containing 1% bovine serum 
albumin. Tht samples were then exposed overnight at 4 oc to affin-
ity-purified rabbit antibodies to human type VI co llagen [1 9] and 
human pl asma fibronectin (Accurate Chemical & Scientific Corp. , 
W estbury, NY) . The sections were washed in TBS for 60 min with 
fi ve changes, and then incubated with tetramethyl rhodamine-
isothiocyanate- conjugated goat anti-rabbit IgG secondary antibod-
ies (Miles Laborator ies, Inc., Elkhart, IN). After a 60-min incuba-
tion at room temperature, the sections were washed in TBS with 
fi ve changes fo r 60 min , rinsed with distill ed water, air dried, 
mounted with Fluoromount (Fisher Scientific, Fairlawn, NJ) , and 
examined with a fluo rescence microscope (Optiphot, Nikon Inc., 
Garden City , NY) , equipped with filters for detection of fluorescein 
isothiocyanate and tetramethyl rhodamine-isothiocyanate. Repre-
sentative secttons were photographed using Tri-X film (Eastman 
Kodak Co.). In control reactions, the primary antibody was omitted 
or replaced with sera from non-immunized animals. Only a faint 
uniform background was observed in all controls. 
Peroxidase- anti-peroxidase (PAP) immunostaining was a slight 
modification of the method previously described in detail [20] . 
Briefly , 5-,um-thick sections were incubated in 0.01 M HCI con-
Case 2 
57/F 
10/ 1986 
A,T,L 
0.8 X 109/l 
Case 3 
74/F 
9/1989 
A,T,L 
3.4 X 109/l 
Case 4 
69/F 
5/1989 
A,L 
6.4 X 109/ l 
raining 10 U / ml pepsin (Sigma C hemica l Co., St. Louis, MO). 
Endogenous peroxidase ac tivity was blocked by incubating the sec-
tions in 0.3% hydrogen peroxide in methyl alcohol. To prevent 
non-specific antibody binding, the sections were pre-incubated for 
30 min in TBS containing 1% bovine serum albumin. For detection 
ofTGF-,8 protein by immunostaining, sections were first incubated 
with an affini ty-purified rabbit anti - T GF-,8 antibody (R and D 
Systems Inc., Minneapolis, MN). Swine anti-rabbit antiserum (Ac-
curate C hemical & Scientific Corp.) was then used as the linking 
antibody, and the sections were incubated with rabbit PAP (Accu-
rate Chemical & Scientific Corp.) . Peroxidase activity was detected 
by incubation with 0.05% 3,3' -diaminobenzidine tetrahydrochlor-
ide in 0.01 % H 20 2 • 
RESULTS 
The biopsy specimens obtained from the four patients studied here 
displayed the characteristic features of diffuse fasci itis w ith eosino-
philic tissue infiltrates as described previously in patients with EMS 
l4 ,5,7]. In all cases, the epidermis appeared normal on histopatho-
logic examination. A striking inflammatory cell infi ltra te consisting 
mainly of plasma cells, lymphocytes, and abundant eosinophils was 
present throughout the dermis and fascia . Many eosinophils ap-
peared to be degranulating, and eosinophilic granules were seen 
scattered throughout the tissue. Moderate perivascular inflamma-
tion without vessel wall necrosis was p·resent. The fascia was mark-
edly thickened, and heavily infiltrated with th ick bundles of colla-
gen that merged with the thickened interlobular septa of the 
panniculus (Fig 1). 
When the affected tissues were examined for im munolocaliza-
tion of type VI collagen, a marked accumulation of epitopes for this 
Figure 1. Histopathology of the full -thickness skin biopsy specimen from 
case 1. The derm1s IS moderately thickened without apparent dermal sclero-
SIS. The fascia IS markc:dly thickened and demonstrates excessive collagen 
deposmon. An mtense mflammatory cell _mfil trate containing lymphocytes, 
plasma cells,_ and abundant eosu10pluls IS observed throughout the tissue 
although It IS more prominent in the fascia (hematoxylin and eosin) . e, 
ep1derm1s; d, dermts; a, adtpose tissue; f, fasc ia. Bar, 1 mm. 
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Figure 2. Indirect immunofluorescence staining for type_ VI collagen. A 
full-thickness skin-b iopsy spec imen was excised fro m a patient Wi th d11fuse 
fasc iitis. A, upper dermis and epidermis (c); B, fasc ial r egion of the same 
ti ssue section as in A. The exposure time was the sam e 111 A and B, and the 
prints were reproduced under identica l cond itions. The immunoreaction in 
fascia is more intense than in dermis. Bar, 50 Jlm . 
protein was observed in the fascia (Fig 2). To compare the relative 
amounts of the protein epitopes detectable in dermis and fascia, all 
specim.ens were processed in parall el and photographed under !den-
tical conditions of exposure time. T his approach permitted a semi-
quantitat ive assessment of the intensity of immunofluorescence. As 
shown in Tab le ll, there was a marked increase in the staining of the 
fascia with antibodies for type VI collagen. When in situ hybridiza-
tion studies were performed em.p\oyin.g an Q2(Vl) collagen-specific 
eDNA, a clearly positive hybridization signal was observed 
throughout the fascia (Fig 3). T he hybridi zation signal was consi-
derabl y more intense in the fasc ia, as compared to the adjacent 
dermis. Immunolocalization of fi.bronectin epitopes also showed 
T H E JOURNAL OF INVESTIGATIVE DERMATOLOGY 
Table II. Comparison of the Relative Expression of Type VI 
Col lagen and TGF-P1 Genes and the Respective Proteins in the 
Dermis and Fascia from Four Patients with Diffuse Fasciitis 
Associated with EMS• 
Type VI collagen 
a2(VI) collagen mRNA 
TGF-{1 protein 
TGF-{11 mRNA 
D ermis 
+ 
+ 
0 
0 
Fascia 
+++ 
++ 
++ 
+++ 
• Semiquanricacive assessment of the levels of protein epitopes, as detected by indirect 
immunofluorescence , and the presence of the corresponding mRNA, as detected by in 
siru hybridi zations, was performed as described in the text. The comparisons are based 
on evaluation of the same tissue specimens. 
much higher intensity of immunofluorescence in the fascia com-
pared to dermis (Fig 4), indicating increased deposition of fibronec-
tin in the fascia. 
Recent studies have implicated TGF-/]1 in the pathogenesis of a 
variety of fibrotic diseases (21- 24]. These observations coupled to 
our recent demonstration of elevated TGF-/]1 gene expression in 
involved tissue in cases of loca lized scleroderma (generalized mor-
phea) and diffuse fasciitis not associated with L-tryptophan inges-
tion [13) prompted us to investigate the presence and expression of 
TGF-/]1 in dermal and fascial tissues from the patients studied here. 
As shown in Fig SA, B, the presence ofTGF-fJ protein was demon-
strated immunohistochemica lly in association with a subpopulation 
of fibroblastic cells in the affected fascia, whereas the upper dermis 
was largely devoid of TGF-,8 epitopes. As reported previously, the 
basal keratinocytes of the epidermis were found to contain protein 
epitopes reacting with antibodies to TGF-,8 (Fig SA) . To examine if 
the selective deposition ofTGF-,8 protein in the fascia demonstrated 
by immunohistochemistry was due to local synthesis of the cyto-
kine, we performed in situ hybridizations with a human sequence-
specific TGF-jl1 eDNA. The resul ts, illustrated in Fig SC, showed 
that the expression of the TGF-jl1 gene was clearly detectable in the 
affected fascia. In contras t, no cells with positive hybridization sig-
nals could be demonstrated in the dermis or in the sub-epidermal 
region (not shown). 
There was no preferential localization of fibroblasts with positive 
hybridization signals for type VI collagen or TGF-/]1 mRNA in 
proximity of eosinophils. Thus, the presence of eosinophils and the 
activation of type VI co llagen and TGF-,81 gene expression in fibro-
blasts displayed a discordant spatial distribution within the tissues. 
Furthermore, the presence of abundant eosinophils at locations dis-
tant from activated fibrobl asts and in areas displaying no hybridiza-
tion signals suggests that direct eosinophil / fibroblast interactions 
may not be involved in the stimulation of fibroblast collagen synthe-
sis or in the enhanced expression ofTGF-,81 gene in these patients. 
However, these observations do not exclude the possible role of 
eosinophil-derived soluble products in such activation. 
DISCUSSION 
Cutaneous involvement is one of the most frequent and prominent 
clinical manifestations of EMS [ 4 - 8]. The most characteristic cuta-
neous change in the chronic phase of the disease is diffuse fasciitis 
with extensive thickening, inflammation, and fibrosis of the fascia. 
The mechanisms responsible for the excessive deposition of extra-
cel lular matrix components in the affected fascia of patients with 
EMS are not known at the present time. In a previous study, we 
demonstrated that the affected integument of patients with EMS 
displayed elevated expression of the genes for type I procollagen [4]. 
The expansion ofknowledge regarding the phenotypic heterogene-
ity of collagens has renewed the interest in the potential role of 
newly discovered genetica lly distinct collagens in human patho-
logic processes . Recent studies have sug gested that type VI collage!\ 
represents a major fraction of connective tissue collagens in a variety 
VOL. 96, NO. I JANUARY 1991 
Figure 3. In situ hybridization of fascia with an a2(VI) collagen eDNA. 
Note the presence of autoradiographic grains representative of radiolabeled 
cD NA/ mRNA hybrids indicating expression of type VI collagen genes 
within the les ional area. A, bright field; B, dark field image of A (hematoxy-
lin counterstain). Bar, 100 pm. 
of tissues, including the skin [15,19 ,25]. In addition , we recentl y 
found that type VI co ll agen gene expression is increased in affected 
skin from patients with diffuse scl eroderma [26], a disease t hat, as 
with diffuse fasciitis, is also characterized by severe cutaneous fibro-
sis. It was of interest, therefore, to determine if fascia from patients 
with EMS displayed similar abnormalities in th e expression of type 
VI coll agen. Our results clearly ind icate that th e increased expres-
sion of extracellular matrix genes in EMS is no t confined to type I 
procollagen, because increased expressio n of type VI collagen genes 
as well as accumu lation of the correspondin g protein epitopes could 
be demonstrated in the affected fascia . 
The prominent ro le th at TGF-P1 r lays in the regulation of fi-
broblast co nnective tissue production l9 - 12,21 J has sugges ted that 
this pleiotropic cytokine may be involved in the initiation, develop-
ment, or progression of fibrosis in a var iety of diseases of humans 
and experimental animals. E levated expression ofTGF-,81 genes has 
been shown in genera lized morphea and in diffuse fasciitis not asso-
ciated w ith L-tryptophan ingestion (13]. diffuse scleroderma [22]. 
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Figure 4. Indirect immunofluorescence staining for fibronectin of a full-
thickness skin-biopsy specimen excised from a patient with diffuse fasciitis . 
A, uppt:r dermis and epidermis (e); B, fasc ial region of the same tissue section 
as in A. The exposure time was the same in A and B, and the prints were 
reproduced under identical conditions. The immunoreaction is more intense 
in fascia than in dermis. Bar, 50 pm. 
vitreo-retinal fibrosis [23]. bleomycin-induced pulmonary fibrosis 
in hamsters [24]. and liver injury fo llowing ceLt administration to 
rats [27] . Increased expression of the TGF-P1 gene and accumula-
tion of this cytokine in the extracellul ar m atrix of the affected fascia 
of patients with EMS were demonstrated in the present study. These 
results suggest, therefore, that TGF-P1 may be intimate ly involved 
in th e pathogenesis of th e diffuse fasciitis in patients with EMS. 
Furthermore, our studies demonstrated that the e levated expression 
of the TGF-,81 gene was confined to fibroblastic ce lls in the affected 
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fascia . These results are in agreement with previous in vitro obser-
vations indicatin g that fibroblasts are capable of the production of 
TGF-fJ1 and that th ey can increase th e expression ofTGF-fJ1 genes 
in an autocrine manner upon exposure to this growth factor [28]. 
Although normal fascia was not examined in the present study, in 
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Figure 5. Express ion ofTGF-.8 in diffuse fasciitis. A, B: peroxidase-anti-
peroxidase stainin g for TGF-.8 protein. Note positive immunoreaction in 
association with cells of lower epidermis (A) and within a subpopulation of 
fibroblastic ce lls in the fascia (B, arrow), whereas the majority o f the cells are 
negative (B, opetJ arrows). C: In situ hybridization with a eDN A for TGF-.81 • 
Note the presence of autoradiographic grains representative of radiolabeled 
cDNA/ mRNA hybrids demonstrating express ion of the TGF-.81 gene in the 
fasc ia by a subpopulation of apparently fibrobl asti c cells (arrows) . Most of the 
cells, however, are negative (ope11 arrows), in a pattern resembling that noted 
for TGF-.81 protein (hematoxylin countersta in). Bar, 50 ttm. 
situ hybridizations of normal skin carried out previously fail ed to 
show any significant expression ofTGF-fJ1 and type I collagen (13] 
or of type VI coll agen genes in the fascia [26] . Furthermore, the 
fascia in th ese samples consisted of a very thin layer of tissue con-
taining few elongated fibroblasts w ith scanty extracellular matrix. 
Also, examination of histologically normal-appearing fa scia from 
full-thickness skin biopsies from patients with systemic sclerosis of 
recent onset did not show any evidence of expression of the genes 
for type I collagen and TGF-fJ1 (13] or for type VI collagen (26]. The 
results presented here suggest, therefore, that activated T cells 
present in the affected tissues in EMS-associated diffuse fasciit is 
produce TGF-fJ1 locally. The cytokine may th en interact with fibro-
blasts and induce its own expression in these cells. The locally pro-
duced TGF-fJ1 may also be rel eased and may bind to the extracellular 
matrix. The continued presence of this cytokine would cause persist-
ent stimulation of adjacent fibroblastic cells resulting in increased 
production of type I and VI coll agens and fibronectin leading to the 
development of tissue fibrosis . 
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